Company intelligence / Profile preview
BioXyTran, Inc.
Boston, Massachusetts, United Statesbioxytraninc.com ↗
- Ownership
- Public · BIXT
- Development stage
- Phase 2
01
Overview
BioXyTran has demonstrated strong efficacy in early clinical trials of its lead galectin antagonist ProLectin-M for COVID‑19, with peer-reviewed studies showing rapid viral clearance and symptom resolution. The company’s approach—blocking galectins to prevent viral entry—has been validated by advanced NMR spectroscopy and two double-blind placebo-controlled trials reporting a “100% responders rate.” No serious adverse events have been reported. The company is advancing toward Phase III registrational trials in India and preparing further studies in the US and Europe. Preclinical work on avian influenza shows promise for rapid outbreak containment without culling.[4][6][8]
- Therapeutic areas
- DermatologyPulmonologyNeurologyInfectious Diseases
- Modalities
- Small molecules (galectin antagonists)Complex carbohydrates (carbohydrate drug design)Oxygen-carrying molecules derived from hemoglobin[5][2]
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Joint venture with The Heme Foundation to develop a universal oxygen carrier; seeking partnerships with organizations/government agencies for avian flu program deployment.[7][9]
04
Financials
- Market cap
- $2.3M
- Total revenue
- $0
- Enterprise value
- $3M
Beyond the preview
Go deeper on BioXyTran, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioXyTran, Inc..